[1]
Fiorillo, A.; Ventriglio, A.; Sampogna, G.; Falkai, P. Innovations in psychiatry: Challenges and future directions. Int. Rev. Psychiatry, 2022, 34(7-8), 659-662.
[http://dx.doi.org/10.1080/09540261.2022.2153011] [PMID: 36586124]
[http://dx.doi.org/10.1080/09540261.2022.2153011] [PMID: 36586124]
[2]
Kalin, N.H. Scientific advances supporting new and improved treatment strategies in psychiatry. Am. J. Psychiatry, 2021, 178(5), 365-368.
[http://dx.doi.org/10.1176/appi.ajp.2021.21030290] [PMID: 33979538]
[http://dx.doi.org/10.1176/appi.ajp.2021.21030290] [PMID: 33979538]
[3]
Mosca, A.; Chiappini, S.; Miuli, A.; Mancusi, G.; Santovito, M.C.; Carlo, F.D.; Pettorruso, M.; Corkery, J.M.; Canessa, C.; Martinotti, G.; Giannantonio, M.D. Ibogaine/Noribogaine in the treatment of substance use disorders: A systematic review of the current literature. Curr. Neuropharmacol., 2022, 21, 2178-2194.
[http://dx.doi.org/10.2174/1570159X21666221017085612] [PMID: 36263479]
[http://dx.doi.org/10.2174/1570159X21666221017085612] [PMID: 36263479]
[4]
Corkery, J.M.; Martinotti, G.; Schifano, F. Contribution of drugs to drownings in Scotland, 1996-2020. Curr. Neuropharmacol., 2022, 2022, 2217-2226.
[PMID: 36043796]
[PMID: 36043796]
[5]
Dell’Osso, B.B.A.; Conca, A.P.M.; Salvi, V.; Siracusano, A.; Zaffora, C.; De Berardis, D.; Di Giannantonio, M. Therapeutic appropriateness of Cariprazine in the management of Schizophrenia: Experts’ Opinion using a Delphi Approach. Curr. Neuropharmacol., 2021, 22(4), 415-426.
[6]
Manning, K.; Wang, L.; Steffens, D. Recent advances in the use of imaging in psychiatry: Functional magnetic resonance imaging of large-scale brain networks in late-life depression. F1000 Res., 2019, 8, 1366.
[http://dx.doi.org/10.12688/f1000research.17399.1] [PMID: 31448089]
[http://dx.doi.org/10.12688/f1000research.17399.1] [PMID: 31448089]
[7]
Pedrini, M.; Cao, B.; Nani, J.V.S.; Cerqueira, R.O.; Mansur, R.B.; Tasic, L.; Hayashi, M.A.F.; McIntyre, R.S.; Brietzke, E. Advances and challenges in development of precision psychiatry through clinical metabolomics on mood and psychotic disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2019, 93, 182-188.
[http://dx.doi.org/10.1016/j.pnpbp.2019.03.010] [PMID: 30904564]
[http://dx.doi.org/10.1016/j.pnpbp.2019.03.010] [PMID: 30904564]